Efficacy of Dry Needling in Reducing Pain During Sexual Intercourse

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorUniversité de Sherbrooke

About this trial

Chronic vulvar pain is a highly prevalent and debilitating condition affecting up to 16% of women. The most common subtype of vulvar pain, provoked vestibulodynia (PVD), is characterized by a sharp pain at the entry of the vagina in response to pressure or attempted vaginal penetration. Women with PVD not only present with psychological distress and significant disruption in all aspects of sexual function, but they are also confronted with limited effective treatment options. Dry needling (DN) could fill this therapeutic gap. Similar to acupuncture, this approach involves the insertion of fine needles into the tissues. However, its mechanisms of action are quite different. DN specifically targets muscle tension/stiffness, which has been shown to play a key role in PVD. After designing a DN treatment protocol tailored to the affected muscles in PVD, our randomized pilot study confirmed that our state-of-the-art DN treatment protocol is feasible and acceptable for treating PVD and the promising findings obtained provide support for conducting the proposed large-scale study.

The proposed multicenter randomized controlled trial aims to establish the efficacy of DN for reducing pain in women with PVD. Women will be randomized to receive either sham or real DN for 8 weekly sessions. Validated outcome measures will be assessed at baseline, post-treatment and at the 6-month follow-up.

The current proposal addresses the urgent need to develop novel treatment options for women with PVD. If proven effective, DN could be proposed as a first-line low-risk treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women reporting vulvo-vaginal pain during intercourse for >3 months with an average pain intensity of ≥5/10 on a numerical rating scale (NRS);

Confirmed diagnosis of provoked vestibulodynia by a gynecologist of our team following a standardized gynaecologic exam.

Disqualifiers

Other urogynecological and vulvar pain conditions (e.g., unprovoked pain, deep dyspareunia, dermatological condition);

Prior vulvovaginal or pelvic surgery;

Current pregnancy;

Postmenopausal status;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Real dry needling

    Other intervention

    The intervention will consist of real dry needling applied to the pelvic floor, hip, and lower back muscles, accompanied by an education component, delivered over eight consecutive weekly sessions.

  • Sham dry needling

    Other intervention

    The same treatment regimen will be applied using sham, non-penetrating, needles.

Treatment groups

170 Participants
are divided into 2 treatment groups
Group A: Real dry needlingExperimental treatment 1 intervention
Group B: Sham dry needlingSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in pain intensity during intercourse

To assess changes in pain intensity during intercourse (Numerical Rating Scale (NRS), ranging from 0 to 10, where 0 is no pain at all, and 10 is the worst pain ever).

Time frame
Baseline, 2-week post-treatment evaluation, 6-month follow-up assessment

Secondary outcomes

1

Change in pain quality

To assess changes in the sensory, affective, and evaluative components of pain (McGill-Melzack Questionnaire). Minimum value: 0, Maximum value: 77, higher scores indicate a worse outcome (higher pain).

Time frame
Baseline, 2-week post-treatment evaluation, 6-month follow-up assessment
2

Change in sexual function

To assess changes in sexual function (Female Sexual Function Index - FSFI). Minimum value: 2, Maximum value: 36, lower scores indicate a worse outcome (low sexual function).

Time frame
Baseline, 2-week post-treatment evaluation, 6-month follow-up assessment
3

Change in sexual distress

To assess changes in sexual distress (Female Sexual Distress Scale - FSDS). Minimum value: 0, Maximum value: 52, higher scores indicate a worse outcome (higher sexually-related distress).

Time frame
Baseline, 2-week post-treatment evaluation, 6-month follow-up assessment
4

Change in pain catastrophizing

To assess changes in pain catastrophizing (Pain Catastrophizing Scale - PCS). Minimum value: 0, Maximum value: 52, higher scores indicate a worse outcome (higher pain catastrophizing).

Time frame
Baseline, 2-week post-treatment evaluation, 6-month follow-up assessment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Université de Sherbrooke

Lead sponsor

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Collaborator

Cigonia

Collaborator

CHU de Quebec-Universite Laval

Collaborator

Kinatex l'Ormière

Collaborator